(Q38030454)

27 August 2017

title

Evolution of insulin development: focus on key parameters (English)

1 reference

27 August 2017

1 reference

ChEBI release 2020-05-28

Joseph M Tibaldi

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

27 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

29

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

590-619

1 reference

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Refining basal insulin therapy: what have we learned in the age of analogues?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Noninjectable methods of insulin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Development of oral insulin: progress and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Landmark perspective: Protamine insulin. Hagedorn's pioneering contribution to drug delivery in the management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Recombinant DNA technology in the treatment of diabetes: insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

21 January 2018

Insulin Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Very pure porcine insulin in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

The first protein ever synthesized in vitro--a personal reminiscence of the total synthesis of crystalline insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Expression in Escherichia coli of chemically synthesized genes for human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin glulisine in the management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin glulisine: a faster onset of action compared with insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Premixed insulin treatment for type 2 diabetes: analogue or human?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

High-dose insulin therapy: is it time for U-500 insulin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Comment on: Ferrannini. Learning from glycosuria. Diabetes 2011;60:695-696.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Inhaled insulin: overview of a novel route of insulin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Targeting insulin and insulin-like growth factor signalling in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Diabetes mellitus and risk of bladder cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Diabetes mellitus and risk of breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

The type 1 insulin-like growth factor receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Hyperinsulinemia potentiates activation of p21Ras by growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Enhanced insulin signaling via Shc in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Molecular mechanisms of insulin resistance that impact cardiovascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Novel insulin analogues and its mitogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Mitogenic action of insulin: friend, foe or 'frenemy'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Diabetes mellitus and prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

U-500 insulin: why, when and how to use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0034-8

10.1007/S12325-012-0034-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1013035423

0 references

1 reference